8 research outputs found
Representation of the 606 neurological patients in the clinical groups.
<p>Each group shows the percentage of patients with high CSF WBC, high CSF proteins and high CSF neopterin. The inflammatory/immune-mediated group had a significantly elevated percentage of high CSF WBC (<sup>*</sup>X<sup>2</sup>â=â27.91, p<0.001), high CSF proteins (<sup>Κ</sup>X<sup>2</sup>â=â17.51, p<0.001) and high CSF NP (<sup>Ί</sup>X<sup>2</sup>â=â103.73, p<0.001) compared with the other groups.</p
Patients with CSF neopterin levels below 61/l (nâ=â550).
<p>Out of 550 patients with CSF neopterin levels below 61 nmol/l, 68 patients had altered CSF proteins, and nine had altered CSF leucocytes. CSF NP: cerebrospinal fluid neopterin. The results are shown as the median and interval in brackets.</p
CSF biochemical values from subjects with CNS infections and peripheral infections.
<p>*Significant values were observed in Total Group 1 vs Total Group 2 (U-Mann Whitney test). The data for the CSF variables are shown as median and range in brackets. CSF: cerebrospinal fluid, WBC: white blood cells.</p
ROC curve to determine the new CSF neopterin cut-off.
<p>The samples were classified into two groups according to the condition that they presented either bacterial/viral central infection (nâ=â68) or peripheral infection (nâ=â52). The area under the curve was 0.934 (range: 0.883â0.985) with 61 nmol/l as the new cut-off. The sensitivity was 91.3%, and the specificity was 88.5%.</p
Patients with CSF neopterin levels above 61/l (nâ=â56).
<p>*Inflammatory/immune-mediated group had significantly elevated CSF neopterin (X<sup>2</sup>â=â35.01, p<0.001), CSF proteins (X<sup>2</sup>â=â12.71, pâ=â0.002) and CSF leukocytes (X<sup>2</sup>â=â6.23, pâ=â0.044) compared with the other groups. Moreover, up to 69.6% of the patients more frequently had CSF NP>61 nmol/L. Out of 56 patients with a CSF neopterin level above 61 nmol/l, 13 patients had altered CSF proteins and four had altered CSF leucocytes.</p><p>AGS: Aicardi-GoutiĂšres syndrome; ARCI: arthrogryposis, renal tubular dysfunction, cholestasis, ichthyosis syndrome; anti-NMDA encephalitis: anti-(N-methyl D-aspartate) receptor encephalitis; CINCA: chronic infantile neurological, cutaneous and articular syndrome; VLCAD: very long-chain acyl-CoA dehydrogenase; CSF NP: cerebrospinal fluid neopterin; WBC: white blood cells. Dist: disturbances. The results are shown as the median and interval in brackets.</p
Number of hospitalized and outpatient pertussis cases according to age group.
<p>mo. months; y. years.</p
Age, duration of cough and diagnostic delay in pertussis cases.
<p>Age, duration of cough and diagnostic delay in pertussis cases.</p
Vaccination status in hospitalized and outpatient cases.
<p>Vaccination status in hospitalized and outpatient cases.</p